Weilin Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Weilin Sun has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Jingyu Deng
Department of Gastric Surgery, Tianjin Medical University Cancer Institute & Hospital; National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin; Tianjin Key Laboratory of Digestive Cancer; Tianjin’s Clinical Research Center for Cancer, Tianjin, China
2 shared publications Zizhen Wu
Department of Gastroenterology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin; Tianjin’s Clinical Research Center for Cancer, Tianjin, China
2 shared publicationsA. DeMichele
1 shared publicationAdriana Corben
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA
1 shared publicationAlexander Bolaender
Program in Chemical Biology, Sloan Kettering Institute, New York, USA
1 shared publicationAnanda Rodilla Martin
Program in Chemical Biology, Sloan Kettering Institute, New York, USA
1 shared publication
Latest Publications
- Open Access
- 15 July 2022
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 10 (7) , e005063
CD40×HER2 bispecific antibody overcomes the CCL2-induced trastuzumab resistance in HER2-positive gastric cancer
Background There was much hard work to study the trastuzumab resistance in HER2-positive gastric cancer (GC), but the information which would reveal this abstruse mechanism is little. In this study, we aimed to investigate the roles of tumor cell-derived CCL2 on trastuzumab resistance and overcome the resistance by treatment with the anti-CD40-scFv-linked anti-HER2 (CD40 ×HER2) bispecific antibody (bsAb). Methods We measured the levels of CCL2 expression in HER2-positive GC tissues, and revealed biological functions of tumor cell-derived CCL2 on tumor-associated macrophages (TAMs) and the trastuzumab resistance. Then, we developed CD40 ×HER2 bsAb, and examined the targeting roles on HER2 and CD40, to overcome the trastuzumab resistance without systemic toxicity. Results We found the level of CCL2 expression in HER2-postive GC was correlated with infiltration of TAMs, polarization status of infiltrated TAMs, trastuzumab resistance and survival outcomes of GC patients. On exposure to CCL2, TAMs decreased the M1-like phenotype, thereby eliciting the trastuzumab resistance. CCL2 activated the transcription of ZC3H12A, which increased K63-linked deubiquitination and K48-linked auto-ubiquitination of TRAF6/3 to inactivate NF-κB signaling in TAMs. CD40 ×HER2 bsAb, which targeted the CD40 to restore the ubiquitination level of TRAF6/3, increased the M1-like phenotypic transformation of TAMs, and overcame trastuzumab resistance without immune-related adversary effects (irAEs). Conclusions We revealed a novel mechanism of trastuzumab resistance in HER2-positive GC via the CCL2-ZC3H12A-TRAF6/3 signaling axis, and presented a CD40 ×HER2 bsAb which showed great antitumor efficacy with few irAEs.
- 15 July 2022
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 10 (7) , e005063
Open AccessCD40×HER2 bispecific antibody overcomes the CCL2-induced trastuzumab resistance in HER2-positive gastric cancer
Background There was much hard work to study the trastuzumab resistance in HER2-positive gastric cancer (GC), but the information which would reveal this abstruse mechanism is little. In this study, we aimed to investigate the roles of tumor cell-derived CCL2 on trastuzumab resistance and overcome the resistance by treatment with the anti-CD40-scFv-linked anti-HER2 (CD40 ×HER2) bispecific antibody (bsAb). Methods We measured the levels of CCL2 expression in HER2-positive GC tissues, and revealed biological functions of tumor cell-derived CCL2 on tumor-associated macrophages (TAMs) and the trastuzumab resistance. Then, we developed CD40 ×HER2 bsAb, and examined the targeting roles on HER2 and CD40, to overcome the trastuzumab resistance without systemic toxicity. Results We found the level of CCL2 expression in HER2-postive GC was correlated with infiltration of TAMs, polarization status of infiltrated TAMs, trastuzumab resistance and survival outcomes of GC patients. On exposure to CCL2, TAMs decreased the M1-like phenotype, thereby eliciting the trastuzumab resistance. CCL2 activated the transcription of ZC3H12A, which increased K63-linked deubiquitination and K48-linked auto-ubiquitination of TRAF6/3 to inactivate NF-κB signaling in TAMs. CD40 ×HER2 bsAb, which targeted the CD40 to restore the ubiquitination level of TRAF6/3, increased the M1-like phenotypic transformation of TAMs, and overcame trastuzumab resistance without immune-related adversary effects (irAEs). Conclusions We revealed a novel mechanism of trastuzumab resistance in HER2-positive GC via the CCL2-ZC3H12A-TRAF6/3 signaling axis, and presented a CD40 ×HER2 bsAb which showed great antitumor efficacy with few irAEs.
- Open Access
- 3 August 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-19
Chemical tools for epichaperome-mediated interactome dysfunctions of the central nervous system
Diseases are a manifestation of how thousands of proteins interact. In several diseases, such as cancer and Alzheimer’s disease, proteome-wide disturbances in protein-protein interactions are caused by alterations to chaperome scaffolds termed epichaperomes. Epichaperome-directed chemical probes may be useful for detecting and reversing defective chaperomes. Here we provide structural, biochemical, and functional insights into the discovery of epichaperome probes, with a focus on their use in central nervous system diseases. We demonstrate on-target activity and kinetic selectivity of a radiolabeled epichaperome probe in both cells and mice, together with a proof-of-principle in human patients in an exploratory single group assignment diagnostic study (ClinicalTrials.gov Identifier: NCT03371420). The clinical study is designed to determine the pharmacokinetic parameters and the incidence of adverse events in patients receiving a single microdose of the radiolabeled probe administered by intravenous injection. In sum, we introduce a discovery platform for brain-directed chemical probes that specifically modulate epichaperomes and provide proof-of-principle applications in their use in the detection, quantification, and modulation of the target in complex biological systems.
- 3 August 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-19
Open AccessChemical tools for epichaperome-mediated interactome dysfunctions of the central nervous system
Diseases are a manifestation of how thousands of proteins interact. In several diseases, such as cancer and Alzheimer’s disease, proteome-wide disturbances in protein-protein interactions are caused by alterations to chaperome scaffolds termed epichaperomes. Epichaperome-directed chemical probes may be useful for detecting and reversing defective chaperomes. Here we provide structural, biochemical, and functional insights into the discovery of epichaperome probes, with a focus on their use in central nervous system diseases. We demonstrate on-target activity and kinetic selectivity of a radiolabeled epichaperome probe in both cells and mice, together with a proof-of-principle in human patients in an exploratory single group assignment diagnostic study (ClinicalTrials.gov Identifier: NCT03371420). The clinical study is designed to determine the pharmacokinetic parameters and the incidence of adverse events in patients receiving a single microdose of the radiolabeled probe administered by intravenous injection. In sum, we introduce a discovery platform for brain-directed chemical probes that specifically modulate epichaperomes and provide proof-of-principle applications in their use in the detection, quantification, and modulation of the target in complex biological systems.
- Open Access
- 30 April 2021
- Published by Springer Nature in Cell Death & Disease
- Vol. 12 (5) , 1-12
DNMT3A-mediated silence in ADAMTS9 expression is restored by RNF180 to inhibit viability and motility in gastric cancer cells
ADAMTS9 belongs to the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) protein family, and its expression is frequently silenced due to promoter hypermethylation in various human cancers. However, the underlying mechanisms remain largely unknown. In this study, we investigated the inhibitory effects of ADAMTS9 on gastric cancer (GC) cells. We initially examined ADAMTS9 protein level in 135 GC and adjacent normal tissue pairs, showing that ADAMTS9 was strikingly decreased in the malignant specimens and patients with low ADAMTS9 expression exhibited more malignant phenotypes and poorer outcome. ADAMTS9 expression was restored in AGS and BGC-823 cells, which then markedly suppressed cellular viability and motility in vitro and in vivo. As ADAMTS9 was enriched in the nuclei of gastric mucosal cells, RNA-sequencing experiment showed that ADAMTS9 significantly altered gene expression profile in BGC-823 cells. Additionally, DNA methyltransferase 3α (DNMT3A) was identified to be responsible for the hypermethylation of ADAMTS9 promoter, and this methyltransferase was ubiquitinated by ring finger protein 180 (RNF180) and then subject to proteasome-mediated degradation. In conclusion, we uncovered RNF180/DNMT3A/ADAMTS9 axis in GC cells and showed how the signaling pathway affected GC cells.
- 30 April 2021
- Published by Springer Nature in Cell Death & Disease
- Vol. 12 (5) , 1-12
Open AccessDNMT3A-mediated silence in ADAMTS9 expression is restored by RNF180 to inhibit viability and motility in gastric cancer cells
ADAMTS9 belongs to the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) protein family, and its expression is frequently silenced due to promoter hypermethylation in various human cancers. However, the underlying mechanisms remain largely unknown. In this study, we investigated the inhibitory effects of ADAMTS9 on gastric cancer (GC) cells. We initially examined ADAMTS9 protein level in 135 GC and adjacent normal tissue pairs, showing that ADAMTS9 was strikingly decreased in the malignant specimens and patients with low ADAMTS9 expression exhibited more malignant phenotypes and poorer outcome. ADAMTS9 expression was restored in AGS and BGC-823 cells, which then markedly suppressed cellular viability and motility in vitro and in vivo. As ADAMTS9 was enriched in the nuclei of gastric mucosal cells, RNA-sequencing experiment showed that ADAMTS9 significantly altered gene expression profile in BGC-823 cells. Additionally, DNA methyltransferase 3α (DNMT3A) was identified to be responsible for the hypermethylation of ADAMTS9 promoter, and this methyltransferase was ubiquitinated by ring finger protein 180 (RNF180) and then subject to proteasome-mediated degradation. In conclusion, we uncovered RNF180/DNMT3A/ADAMTS9 axis in GC cells and showed how the signaling pathway affected GC cells.
- Open Access
- 1 June 2020
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 8 (11) , 680
Should the left gastric artery lymph node be considered as the predictive lymph node for extra-gastric lymph node metastases?
Background: To validate the prognostic impacts of the left gastric artery lymph node (No. 7 LN) metastasis and investigate whether the No. 7 LN metastasis should be considered as the predictive LN for extra-gastric LN metastases. Methods: Between January 2003 and December 2011, a total of 1,586 patients who underwent R0 gastrectomy were retrospected. Patients with LN metastases were divided into three groups: (I) patients with only peri-gastric LN metastases (peri-gastric group); (II) patients with peri-gastric and only No. 7 LN metastases (No. 7 group); and (III) patients with other extra-gastric LN metastases (extra-gastric group). Propensity score matching (PSM) was adopted to accurately evaluate prognoses of all patients after surgery. Results: Of 1,586 patients, 235 (14.82%) were pathologically identified to present with the No. 7 LN metastases. Patients with the No. 7 LN metastases presented the significantly lower survival rate both before and after adjustment by pTNM stage, compared to those without the No. 7 LN metastases. Patients in the No. 7 group were identified to present the significant lower survival rate than those in the peri-gastric group, and to present the similar median overall survival (OS) to those in the extra-gastric group. In addition, patients with extra-gastric LN except No. 7 LN metastases failed to show any superiority of survival outcomes, compared with those with extra-gastric LN metastases including the No. 7 LN metastasis. Conclusions: The No. 7 LN metastases had the crucial survival implications. Nevertheless, the No. 7 LN failed to be considered as the predictive LN for the extra-gastric LN metastases in gastric cancer (GC).
- 1 June 2020
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 8 (11) , 680
Open AccessShould the left gastric artery lymph node be considered as the predictive lymph node for extra-gastric lymph node metastases?
Background: To validate the prognostic impacts of the left gastric artery lymph node (No. 7 LN) metastasis and investigate whether the No. 7 LN metastasis should be considered as the predictive LN for extra-gastric LN metastases. Methods: Between January 2003 and December 2011, a total of 1,586 patients who underwent R0 gastrectomy were retrospected. Patients with LN metastases were divided into three groups: (I) patients with only peri-gastric LN metastases (peri-gastric group); (II) patients with peri-gastric and only No. 7 LN metastases (No. 7 group); and (III) patients with other extra-gastric LN metastases (extra-gastric group). Propensity score matching (PSM) was adopted to accurately evaluate prognoses of all patients after surgery. Results: Of 1,586 patients, 235 (14.82%) were pathologically identified to present with the No. 7 LN metastases. Patients with the No. 7 LN metastases presented the significantly lower survival rate both before and after adjustment by pTNM stage, compared to those without the No. 7 LN metastases. Patients in the No. 7 group were identified to present the significant lower survival rate than those in the peri-gastric group, and to present the similar median overall survival (OS) to those in the extra-gastric group. In addition, patients with extra-gastric LN except No. 7 LN metastases failed to show any superiority of survival outcomes, compared with those with extra-gastric LN metastases including the No. 7 LN metastasis. Conclusions: The No. 7 LN metastases had the crucial survival implications. Nevertheless, the No. 7 LN failed to be considered as the predictive LN for the extra-gastric LN metastases in gastric cancer (GC).
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15_suppl) , 3088
Phase II/pharmacodynamic trial of PD0332991 in patients with breast, colon, germ cell, and epithelial tumors containing amplification of CCND1.
3088 Background: The cell cycle is dysregulated in most patients with epithelial cancers, through activating mutations or overexpression of cell cycle proteins, or loss of cell cycle inhibitors such as p53, p16, etc. A proportion of tumors also have amplification of CCND1, which encodes cyclin D1. In a Phase I trial of the cdk4/6 inhibitor PD0332991 we found prolonged stable disease in patients with several types of epithelial cancer. We now report a phase II trial of PD0332991 in patients with four disease types: breast cancer, Kras-mutant colorectal cancer, resistant germ cell malignancies, and any tumor demonstrated to have amplification of cyclin D1, as assessed by FISH. Methods: Eligible pts were treated with PD0332991 125 mg daily for 21 of 28 days. The primary objective was to determine the progression-free survival in cohorts of 15 patients per tumor type. Secondary objectives include anti-tumor activity, pharmacodynamics (PD) and pharmacokinetics (PK). Results: We screened 79 patients with these characteristics for Rb positivity: 26 had positive staining and were treated. Toxicity was limited to myelosuppression, mainly neutropenia, as had been observed in the phase I study. Of nine patients with colorectal cancer, five had 18F-FLT PET/CT performed before and after about 5 weeks of therapy as a pharmacodynamic marker. Maximum SUV values were computed for tumor (up to five lesions) and lumbar vertebral bodies (sum of five) as a marker of marrow effect. Bone marrow SUV values varied by a factor of three between patients, but intrapatient variability was minimal. Following treatment, marrow SUV values declined by a mean of 21.3% (range +1.7 to -55%). A similar decrease in tumor SUV values was observed (mean 27.5% decrease, range -7.3 to -47.5%), and four of the five patients had a decrease of > 25%. Pharmacokinetic studies are in progress to relate to PD markers of toxicity and activity, and to expand a model derived from Phase I data. Conclusions: PD0332991 is a well-tolerated cell cycle inhibitor with evidence of disease control in patients with various tumor types. Preliminary data in colorectal cancer suggest that FLT PET may provide a pharmacodynamic measure of drug activity.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15_suppl) , 3088
Phase II/pharmacodynamic trial of PD0332991 in patients with breast, colon, germ cell, and epithelial tumors containing amplification of CCND1.
3088 Background: The cell cycle is dysregulated in most patients with epithelial cancers, through activating mutations or overexpression of cell cycle proteins, or loss of cell cycle inhibitors such as p53, p16, etc. A proportion of tumors also have amplification of CCND1, which encodes cyclin D1. In a Phase I trial of the cdk4/6 inhibitor PD0332991 we found prolonged stable disease in patients with several types of epithelial cancer. We now report a phase II trial of PD0332991 in patients with four disease types: breast cancer, Kras-mutant colorectal cancer, resistant germ cell malignancies, and any tumor demonstrated to have amplification of cyclin D1, as assessed by FISH. Methods: Eligible pts were treated with PD0332991 125 mg daily for 21 of 28 days. The primary objective was to determine the progression-free survival in cohorts of 15 patients per tumor type. Secondary objectives include anti-tumor activity, pharmacodynamics (PD) and pharmacokinetics (PK). Results: We screened 79 patients with these characteristics for Rb positivity: 26 had positive staining and were treated. Toxicity was limited to myelosuppression, mainly neutropenia, as had been observed in the phase I study. Of nine patients with colorectal cancer, five had 18F-FLT PET/CT performed before and after about 5 weeks of therapy as a pharmacodynamic marker. Maximum SUV values were computed for tumor (up to five lesions) and lumbar vertebral bodies (sum of five) as a marker of marrow effect. Bone marrow SUV values varied by a factor of three between patients, but intrapatient variability was minimal. Following treatment, marrow SUV values declined by a mean of 21.3% (range +1.7 to -55%). A similar decrease in tumor SUV values was observed (mean 27.5% decrease, range -7.3 to -47.5%), and four of the five patients had a decrease of > 25%. Pharmacokinetic studies are in progress to relate to PD markers of toxicity and activity, and to expand a model derived from Phase I data. Conclusions: PD0332991 is a well-tolerated cell cycle inhibitor with evidence of disease control in patients with various tumor types. Preliminary data in colorectal cancer suggest that FLT PET may provide a pharmacodynamic measure of drug activity.